Phase 3 Prostate Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Male participants who are 18 years of age or older at the time of screening (or the minimum age required by local rules).
• People whose prostate cancer has been confirmed by a tissue or cell sample as adenocarcinoma (a specific type of prostate cancer), without certain aggressive small cell features.
• People whose prostate cancer has spread to other parts of the body, confirmed by a bone scan, CT scan, or MRI.
• People whose side effects from any previous treatment have largely settled down to a mild level or back to how they were before treatment started.
• People who are generally well enough to carry out daily activities with little or no limitation (this is measured using a standard medical scale — confirm with trial site).

Who may not be able to join:

• People with certain medical or psychiatric conditions, including thoughts of suicide or self-harm within the past year or currently, or certain abnormal lab results that the doctor feels make participation unsafe.
• People with serious heart or blood vessel disease.
• People with cancer that has spread to the brain, or with a related condition affecting the lining of the brain or spinal cord.
• People who have already received certain cancer treatments (such as chemotherapy) for their metastatic prostate cancer — though treatment with a specific older type of hormone therapy (first-generation antiandrogen/ADT) is an exception and may be allowed (confirm with trial site).
• People who have taken part in another clinical trial involving an experimental drug or vaccine within the past 30 days.
• People who have used a type of medication called 5-alpha reductase inhibitors within 28 days before joining the trial.
• People who have had surgery recently and have not fully recovered at least 28 days before joining the trial.
• People currently taking or expecting to need certain medications that strongly affect how the body processes drugs (known as strong CYP3A4/5 inhibitors or inducers) — with one exception that may apply within this trial (confirm with trial site).
• People whose kidneys, liver, or other organs are not functioning well enough (confirm with trial site).
• People with a known allergy or sensitivity to the study drugs (mevrometostat or enzalutamide) or any of their ingredients.

Important: Always verify eligibility with the trial site directly before applying.